A Spanish study [123] analyzed the tumor microenvironment immunotypes (TMIT), deriving from the combination of tumor-infiltrating lymphocyte density and PD-L1 expression, such as a biomarker for immunotherapy in 133 ITAC. This evidence concerns the gene CD274 and neoplasm.